Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.

Commitment to Efficiency and Margin Expansion. The Pacira Board and management team are committed to enhancing the company’s operational efficiency and expect to prioritize opportunities to drive ...

and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular ...

and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular ...

sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal. Zilretta, on the other hand, is approved as an extended-release intra-articular therapy providing relief ...

and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular ...

He was discharged home the same day, ambulating with crutches with partial weight-bearing, indicating satisfactory resolution of the motor block from bupivacaine ... 22 mL was administered to the ...

Sciatic nerve pain isn’t just an occasional discomfort—it’s a constant, often debilitating issue that affects millions of adults worldwide. Characterized by sharp, shooting pain radiating ...